Is HOWL or IBIO more profitable?

iBio's return on equity of -53.86% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% iBio N/A -53.86% -46.48%

Does the media prefer HOWL or IBIO?

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. iBio's average media sentiment score of 1.32 beat Werewolf Therapeutics' score of 0.94 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HOWL or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Werewolf Therapeutics N/A N/A -$60.82M -$1.24 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is HOWL or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% PMV Pharmaceuticals N/A -68.98% -62.70%

Does the media favor HOWL or PMVP?

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. Werewolf Therapeutics' average media sentiment score of 0.94 equaled PMV Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HOWL or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Werewolf Therapeutics N/A N/A -$60.82M -$1.24 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is HOWL or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% XBiotech N/A -26.10% -25.06%

Does the media favor HYFT or HOWL?

In the previous week, MindWalk had 19 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 21 mentions for MindWalk and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.94 beat MindWalk's score of 0.21 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HOWL or TLPH more profitable?

Talphera's return on equity of -92.98% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Talphera N/A -92.98% -53.22%

Does the media refer more to HOWL or TLPH?

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. Talphera's average media sentiment score of 1.87 beat Werewolf Therapeutics' score of 0.94 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Werewolf Therapeutics (HOWL) Competitors

$0.43 +0.07 (+18.55%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.42 -0.01 (-2.11%)

As of 07/24/2026 07:34 PM Eastern

Compare

HOWL vs. IBIO, PMVP, XBIT, HYFT, and TLPH

Should you buy Werewolf Therapeutics stock or one of its competitors? MarketBeat compares Werewolf Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Werewolf Therapeutics include iBio (IBIO), PMV Pharmaceuticals (PMVP), XBiotech (XBIT), MindWalk (HYFT), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does Werewolf Therapeutics compare to iBio?

Werewolf Therapeutics (NASDAQ:HOWL) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, iBio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. iBio's average media sentiment score of 1.32 beat Werewolf Therapeutics' score of 0.94 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio's return on equity of -53.86% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
iBio	N/A	-53.86%	-46.48%

iBio has higher revenue and earnings than Werewolf Therapeutics. iBio is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A
iBio	$400K	177.61	-$18.38M	-$0.58	N/A

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 778.22%. iBio has a consensus price target of $5.00, indicating a potential upside of 249.65%. Given Werewolf Therapeutics' higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

iBio beats Werewolf Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to PMV Pharmaceuticals?

Werewolf Therapeutics (NASDAQ:HOWL) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Werewolf Therapeutics currently has a consensus price target of $3.75, suggesting a potential upside of 778.22%. PMV Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 222.58%. Given Werewolf Therapeutics' higher probable upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. Werewolf Therapeutics' average media sentiment score of 0.94 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PMV Pharmaceuticals' return on equity of -68.98% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PMV Pharmaceuticals beats Werewolf Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Werewolf Therapeutics compare to XBiotech?

Werewolf Therapeutics (NASDAQ:HOWL) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

XBiotech is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Werewolf Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Werewolf Therapeutics presently has a consensus target price of $3.75, suggesting a potential upside of 778.22%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Werewolf Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Werewolf Therapeutics' score of 0.94 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Positive
XBiotech	Very Positive

XBiotech's return on equity of -26.10% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
XBiotech	N/A	-26.10%	-25.06%

Summary

Werewolf Therapeutics beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does Werewolf Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Werewolf Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -89.65%. MindWalk's return on equity of -92.61% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

MindWalk has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

MindWalk has higher revenue and earnings than Werewolf Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$15.56M	4.08	-$21.69M	-$0.22	N/A
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A

MindWalk presently has a consensus target price of $5.00, indicating a potential upside of 267.65%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 778.22%. Given Werewolf Therapeutics' higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, MindWalk had 19 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 21 mentions for MindWalk and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.94 beat MindWalk's score of 0.21 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.7% of MindWalk shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MindWalk beats Werewolf Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Talphera?

Werewolf Therapeutics (NASDAQ:HOWL) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. Talphera's average media sentiment score of 1.87 beat Werewolf Therapeutics' score of 0.94 indicating that Talphera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Talphera's return on equity of -92.98% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Talphera	N/A	-92.98%	-53.22%

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Talphera has higher revenue and earnings than Werewolf Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A
Talphera	$30K	2,335.50	-$14.29M	-$0.31	N/A

Werewolf Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Talphera has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 778.22%. Talphera has a consensus price target of $3.00, indicating a potential upside of 122.22%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Talphera beats Werewolf Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.75M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.34	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.84	7.88	10.28	6.07
Net Income	-$60.82M	$23.86M	$3.60B	$331.99M
7 Day Performance	16.03%	-3.82%	-1.27%	-0.63%
1 Month Performance	27.84%	-2.61%	-0.37%	-2.00%
1 Year Performance	-68.60%	32.79%	18.30%	13.62%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	3.3716 of 5 stars	$0.43 +18.5%	$3.75 +778.2%	-68.8%	$20.75M	N/A	N/A	40	High Trading Volume
IBIO iBio	2.8101 of 5 stars	$1.41 +2.9%	$5.00 +254.6%	N/A	$70.05M	$300K	N/A	100	News Coverage Positive News
PMVP PMV Pharmaceuticals	3.698 of 5 stars	$1.31 +2.3%	$4.00 +205.3%	-13.9%	$69.86M	N/A	N/A	50	News Coverage
XBIT XBiotech	0.7905 of 5 stars	$2.24 -0.4%	N/A	-20.1%	$68.29M	N/A	N/A	100	Positive News High Trading Volume
HYFT MindWalk	2.1631 of 5 stars	$1.46 +2.1%	$5.00 +242.5%	N/A	$68.20M	$17.59M	N/A	80	Trending News Earnings Report Analyst Downgrade Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. IBIO, PMVP, XBIT, HYFT, and TLPH

How does Werewolf Therapeutics compare to iBio?

Summary

How does Werewolf Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Werewolf Therapeutics compare to XBiotech?

Summary

How does Werewolf Therapeutics compare to MindWalk?

Summary

How does Werewolf Therapeutics compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. IBIO, PMVP, XBIT, HYFT, and TLPH

How does Werewolf Therapeutics compare to iBio?

Do institutionals & insiders believe in HOWL or IBIO?

Which has more volatility and risk, HOWL or IBIO?

Does the media prefer HOWL or IBIO?

Is HOWL or IBIO more profitable?

Which has preferable earnings and valuation, HOWL or IBIO?

Do analysts rate HOWL or IBIO?

Summary

How does Werewolf Therapeutics compare to PMV Pharmaceuticals?

Do analysts rate HOWL or PMVP?

Does the media favor HOWL or PMVP?

Is HOWL or PMVP more profitable?

Which has more risk & volatility, HOWL or PMVP?

Which has higher earnings and valuation, HOWL or PMVP?

Do institutionals and insiders believe in HOWL or PMVP?

Summary

How does Werewolf Therapeutics compare to XBiotech?

Which has stronger valuation and earnings, HOWL or XBIT?

Which has more risk and volatility, HOWL or XBIT?

Do analysts rate HOWL or XBIT?

Do insiders and institutionals believe in HOWL or XBIT?

Does the media refer more to HOWL or XBIT?

Is HOWL or XBIT more profitable?

Summary

How does Werewolf Therapeutics compare to MindWalk?

Is HYFT or HOWL more profitable?

Which has more risk & volatility, HYFT or HOWL?

Which has stronger earnings and valuation, HYFT or HOWL?

Do analysts rate HYFT or HOWL?

Does the media favor HYFT or HOWL?

Do institutionals and insiders have more ownership in HYFT or HOWL?

Summary

How does Werewolf Therapeutics compare to Talphera?

Does the media refer more to HOWL or TLPH?

Is HOWL or TLPH more profitable?

Do institutionals & insiders believe in HOWL or TLPH?

Which has preferable valuation and earnings, HOWL or TLPH?

Which has more risk and volatility, HOWL or TLPH?

Do analysts rate HOWL or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools